A real-world study confirms the efficacy and safety of semaglutide 2.4 mg in treating obesity. As obesity remains a mounting global health challenge, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has garnered attention for its substantial impact on weight reduction. The study offers valuable clinical insights for practitioners and patients navigating obesity treatment options in varied settings.